Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.
Olix Pharmaceuticals Inc. has released preclinical data from a head-to-head study in obese nonhuman primates (NHPs) showing that OLX-501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound.
Researchers from Yunnan University, Sicagene Bioscience Co. Ltd. and collaborators reported the preclinical efficacy of GS-10c, a GalNAc-conjugated antisense oligonucleotide (ASO) developed to silence serine/threonine kinase 25 (STK25), a lipid droplet-associated kinase implicated in the development of metabolic dysfunction-associated steatotic liver disease (MASLD).
